SynBioBeta Speaker
Stephanie Wisner
Centivax
Co-founder & CBO
Stephanie A. Wisner co-founded the biotech start-up, Centivax, where she is now Chief Business Officer. At Centivax, she has been instrumental in securing over $70M in private financing and $24M in non-dilutive funding from organizations such as the National Institutes of Health (NIH), Department of Defense (DoD), and the United States Navy. She has also advised multiple biotech start-ups on business and commercialization strategy through her consulting business, BioVenture Advising LLC and spent several years at ARCH Venture Partners. In 2022, she was named to the Forbes 30 Under 30 list for Healthcare. She completed her MBA at the University of Chicago Booth School of Business, with concentrations in finance, accounting, and entrepreneurship. She received her Bachelor’s Degree in chemistry and chemical biology from Cornell University and was awarded the Einhorn Discovery Research Grant for her independent research on cancer. Building Backwards to Biotech was an Amazon #1 New Release in the Category of Biotechnology. The book is currently taught as part of bioentrepreneurial programming at multiple top institutions, including Dartmouth College, Cornell University, and others. She is also an Entrepreneur-in-Residence and former Faculty at Cornell University. You can reach Stephanie at bioventureadvising.com.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Stephanie
This Year
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
